Dr Josevania Martins Suspended Over Partner Ozempic Prescriptions Hampstead 2026

Key Points

• Dr Josevania Martins has received an additional six-month suspension following a review by the Medical Practitioners Tribunal Service.
• The Hampstead practitioner prescribed GLP-1 weight loss medications, including Ozempic and Wegovy, to her boyfriend, referred to in proceedings as “Mr B.”
• Dr Martins hid her medical profession from Mr B throughout their relationship, barring him from visiting her residence to maintain the deception.
• The tribunal previously established that Dr Martins created a fictitious clinic name to secure the prescription drugs while concealing her identity.
• Dr Martins defended the prescribing practices by characterizing Mr B’s weight loss requirements as a “medical emergency” and framing her intervention as compassionate care.
• The General Medical Council maintains strict guidelines explicitly prohibiting doctors from prescribing controlled or prescription-only medicines to individuals with whom they share a close personal relationship.

Hampstead (North London News) August 15, 2026 – A private gynaecology and fertility practitioner based in Hampstead has been handed a further six-month suspension by a medical tribunal after prescribing weight loss drugs to her partner while hiding her professional identity from him. Dr Josevania Martins, who manages a private practice in North London, was originally issued a nine-month suspension in October 2025 following a General Medical Council investigation into her prescribing practices. The sanction was extended following a review by the Medical Practitioners Tribunal Service, which assessed her current fitness to practise after she breached fundamental medical regulations regarding self-prescribing and treating relatives or personal partners.

Why Was Dr Josevania Martins Suspended by the Medical Tribunal?

The regulatory action stems from an extensive investigation into Dr Martins’ actions while dating a partner identified in official tribunal documentation as “Mr B.”

According to findings detailed by the Medical Practitioners Tribunal Service, Dr Martins utilized her medical authority to acquire GLP-1 receptor agonists—specifically Ozempic and Wegovy—for Mr B.

Despite using her professional status to order and obtain these prescription-only medications, Dr Martins intentionally concealed her status as a registered medical doctor from Mr B.

Evidence presented to the tribunal demonstrated that Dr Martins implemented deliberate measures to prevent Mr B from discovering her true occupation, including prohibiting him from visiting her home address.

To maintain the secrecy of her profession while simultaneously obtaining the prescription treatments, Dr Martins fabricated the existence of a fake clinic.

The panel determined that she invented the clinic name to process orders and satisfy supply verification protocols, leveraging her legitimate GMC registration to access wholesale pharmaceutical lines under false pretences.

How Did the Doctor Justify Prescribing Ozempic to Her Partner?

Throughout the initial regulatory proceedings in October 2025, Dr Martins defended her actions by maintaining that her intervention was driven by empathy and urgent clinical need.

She submitted to the panel that Mr B’s body weight constituted a “medical emergency,” arguing that immediate pharmaceutical intervention via Ozempic and Wegovy was necessary to safeguard his health.

Dr Martins asserted that her decision to provide the medications was rooted in compassionate care for a partner who required physical intervention.

However, the Medical Practitioners Tribunal Service rejected the argument that a weight management scenario justified overriding standard prescribing protocols, particularly given the total absence of proper clinical oversight, medical history documentation, or informed consent obtained in a standard doctor-patient framework.

The General Medical Council enforces unambiguous operational boundaries regarding treatment of friends, family, and personal partners.

Under GMC guidelines, medical practitioners must avoid prescribing drugs to individuals with whom they have a close personal relationship, except in acute situations where no other medical professional is available and delay would result in serious harm or death. The tribunal concluded that Mr B’s circumstances did not meet the definition of an acute emergency.

What Are the Regulatory Standards Surrounding GLP-1 Weight Loss Drugs?

The case highlights ongoing regulatory scrutiny surrounding the distribution and off-label prescription of GLP-1 medications across the United Kingdom. Medications such as Ozempic (semaglutide) and Wegovy are prescription-only products designated for the treatment of type 2 diabetes and clinical obesity, respectively. UK medical regulations mandate that these treatments must only be initiated following a comprehensive clinical consultation, including an accurate assessment of patient body mass index, prior medical history, and potential contraindications.

What Specific GMC Guidelines Were Violated?

The GMC code of conduct requires doctors to maintain clear boundaries between their professional duties and personal lives. Specifically, the regulatory framework stipulates:

• Practitioners must not prescribe to themselves or anyone with whom they have a close personal relationship.
• Objective medical records must be created and maintained for every patient receiving prescription-only medications.
• Doctors must ensure proper clinical follow-up and monitoring for adverse side-effects when initiating treatments like GLP-1 agonists.
• Misrepresenting professional details or inventing clinical entities compromises the integrity of the pharmaceutical supply chain and constitutes dishonest conduct.

The panel concluded that Dr Martins’ conduct breached core tenets of good medical practice, pointing to the deliberate nature of the deception and the potential health risks posed to Mr B by receiving prescription drugs without formal diagnostic tracking.

Explore More Hampstead News

Cyclist Hospitalised After Pond Street Crash in Hampstead, 2026

It’s Bagels Opens New York-Style Venue in Hampstead 2026

What Background Led to the Current Six-Month Suspension Extension?

Dr Josevania Martins established her professional standing as a specialist running a private clinic in the Hampstead area, concentrating on gynaecological care and fertility treatments.

The clinic served private patients in North London, operating independently from the National Health Service framework.

The initial breach came to the attention of the General Medical Council following reports regarding irregular prescribing activity linked to Dr Martins’ credentials. When the case first came before the Medical Practitioners Tribunal Service in October 2025, the panel found her fitness to practise impaired by reason of misconduct.

The tribunal noted that while Dr Martins was a capable clinician in her specialized field, her willingness to invent a fake clinic and bypass statutory prescribing barriers demonstrated a severe lack of insight into professional standards.

At the conclusion of her original nine-month suspension, a review hearing was convened to assess whether Dr Martins had addressed the underlying deficiencies in her conduct.

The panel determined that her fitness to practise remained impaired, concluding that a further six-month suspension was necessary to protect the public, maintain professional standards, and preserve public confidence in the medical profession.

What Impact Will This Ruling Have on Private Patients and Prescribing Practices?

This development directly affects private healthcare consumers, particularly patients seeking treatment at specialized private clinics across North London and the broader Hampstead area.

For patients of Dr Martins’ Hampstead practice, the continuation of her suspension means her clinic cannot offer services under her direct clinical direction for at least an additional six months.

Patients undergoing active fertility monitoring or gynaecological treatment plans will need to seek alternative registered providers to ensure continuity of care.

More broadly, this decision sends a clear signal to private practitioners and the public regarding the stringent regulation of weight loss medications.

As demand for GLP-1 receptor agonists increases, the tribunal’s ruling reinforces that private doctors cannot bypass statutory prescribing regulations or treat personal acquaintances, regardless of personal motivations or claims of medical necessity. The ruling highlights that the regulatory system prioritizes transparent clinical boundaries and patient safety over informal or unmonitored treatment arrangements.